Piper Sandler raises target for Bristol Myers Squibb stock from USD 75.00 to USD 82.00
Published on 10/02/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock was trading at EUR 54.38 at Lang & Schwarz on October 2, 2026, at 2:33 p.m. CEST. On September 16, 2026, Piper Sandler raised its price target from USD 75.00 to USD 82.00 while maintaining an Overweight rating, as Investing.com reported.
ZENBEXUS delivers a measurable trial gap
On September 25, 2026, Bristol Myers Squibb presented Phase 3 EXCALIBER-RRMM results for ZENBEXUS in relapsed or refractory multiple myeloma. The treatment combination produced a 41.10 percent minimal residual disease-negative complete response rate, versus 20.70 percent for the comparator regimen.
The comparison extended beyond the primary response measure. Overall response reached 88.90 percent with ZENBEXUS versus 76.10 percent with the comparator, while complete response or better reached 45.90 percent versus 24.90 percent. The study included 420 evaluable patients after a median follow-up of 15.7 months.
Revenue beat gives the pipeline context
In the second quarter of 2026, Bristol Myers Squibb reported USD 12.97 billion in revenue against consensus of USD 11.74 billion, according to MarketBeat. Earnings per share came to USD 2.04 versus consensus of USD 1.60, a USD 0.44 difference.
That operating comparison explains why analysts can frame the pipeline as a growth bridge rather than a standalone research story. Piper Sandler's USD 82.00 target is tied to upcoming clinical milestones, while the latest quarterly figures show that established products already support a sizable revenue base.
October reporting date sets the next checkpoint
Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, according to StockTitan. The report will place the latest revenue trend beside clinical updates, making commercial execution and pipeline progress the two measurable parts of the next valuation debate.
For investors, the key contrast is visible in the trial data: 41.10 percent versus 20.70 percent on the response endpoint, alongside the higher 88.90 percent overall response rate. The figures offer a concrete reason for the analyst optimism, but the ongoing clinical and commercialization risks remain part of the valuation equation.
Stock valuation stays tied to execution
Bristol Myers Squibb had a market capitalization of USD 125.5 billion as of October 1, 2026. Its NYSE-listed shares had a 52-week range of USD 42.52 to USD 68.64, leaving the company valued on both current earnings and the prospect of new medicines reaching broader markets.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock facts
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 2, 2026, 2:33 p.m. CEST): EUR 54.38
- Market capitalization: USD 125.5 billion (as of October 1, 2026)
- 52-week range: USD 42.52-68.64 (as of October 1, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
